Fluoride treatment of postmenopausal osteoporosis: age, renal function, and other clinical factors in the osteogenic response.
We report on 61 women with postmenopausal osteoporosis who were treated with either plain sodium fluoride (NaF) capsules or enteric-coated NaF tablets for 4 years, in whom possible therapeutic and toxic effects were monitored. In these patients there was a mean increase in axial bone mineral mass, assessed by neutron activation analysis, of 26.2% +/- 2.4% (SEM) during the 4 years. This corresponds to a decrease in the bone deficit (compared with reference values) of 48.6%. The response was linear over 4 years. The main predictors of the osteogenic response were bone fluoride (r = 0.52, p less than 0.01), serum fluoride (r = 0.50, p less than 0.01), and age (0.39, p less than 0.01). Patients over 65 years of age achieved higher bone fluoride (F) levels and a significantly greater increase in bone mineral than younger patients (32.8 vs. 17.9%, p less than 0.01), associated with an age-related decline in renal function; serum fluoride was significantly and negatively correlated to creatinine clearance (r = -0.52, p less than 0.01). Although the effect of NaF on fracture rate could not be assessed in this uncontrolled study, the major factors associated with the occurrence of new vertebral fractures were the number of vertebral fractures and the bone mineral mass at the beginning of therapy. There was no correlation between vertebral fracture rate and serum or bone fluoride or other parameters of the osteogenic response, but patients who did not experience new vertebral fractures achieved a normal bone mineral content sooner than those who had new fractures during therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Murray
T M
TM
Department of Medicine, University of Toronto, St. Michael's Hospital, Ontario, Canada.
Harrison
J E
JE
Bayley
T A
TA
Josse
R G
RG
Sturtridge
W C
WC
Chow
R
R
Budden
F
F
Laurier
L
L
Pritzker
K P
KP
Kandel
R
R
D000368:Aged; D000375:Aging / Q000473:pathology* / Q000502:physiology; D015519:Bone Density / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000209:etiology; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors; D012969:Sodium Fluoride / Q000009:adverse effects / Q000627:therapeutic use*; D013124:Spinal Injuries / Q000209:etiology; D013608:Tablets, Enteric-Coated
D013608:Tablets, Enteric-Coated; D012969:Sodium Fluoride